| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7235627 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2017
(6 years ago) | |
| US6458924 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2017
(6 years ago) | |
| US8846618 | NOVO | Stable formulation of modified GLP-1 |
Jun, 2022
(1 year, 10 months ago) | |
| US6268343 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2022
(1 year, 8 months ago) | |
| US7615532 | NOVO | Insulin derivatives |
Jun, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
|
US8672898 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 10 months ago) | |
|
US9486588 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 10 months ago) | |
|
US6899699 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 10 months ago) | |
|
US8846618 (Pediatric) | NOVO | Stable formulation of modified GLP-1 |
Dec, 2022
(1 year, 4 months ago) | |
|
US6268343 (Pediatric) | NOVO | Derivatives of GLP-1 analogs |
Feb, 2023
(1 year, 2 months ago) | |
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(10 months ago) | |
|
US8579869 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(4 months ago) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(16 days from now) | |
|
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(6 months from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 5 months from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
|
US8684969 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Apr, 2026
(1 year, 11 months from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
|
US9616180 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(2 years from now) | |
|
US9861757 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Jul, 2026
(2 years from now) | |
|
US9108002 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(2 years from now) | |
| US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
|
US8920383 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
|
US9775953 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
|
US10220155 (Pediatric) | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(2 years from now) | |
|
USRE46363 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2027
(2 years from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
|
US9687611 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Aug, 2027
(3 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
|
US9457154 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Mar, 2028
(3 years from now) | |
| US8937042 | NOVO | Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide |
May, 2029
(4 years from now) | |
|
US8937042 (Pediatric) | NOVO | Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide |
Nov, 2029
(5 years from now) | |
|
US7615532 (Pediatric) | NOVO | Insulin derivatives |
Dec, 2029
(5 years from now) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
|
US9132239 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(8 years from now) | |
Xultophy 100/3.6 is owned by Novo.
Xultophy 100/3.6 contains Insulin Degludec; Liraglutide.
Xultophy 100/3.6 has a total of 45 drug patents out of which 14 drug patents have expired.
Expired drug patents of Xultophy 100/3.6 are:
- US6899699
- US8672898
- US9486588
- US8672898*PED
- US9486588*PED
- US6899699*PED
- US8846618*PED
- US6268343*PED
- US8579869
- US8579869*PED
- US7235627
- US6458924
- US8846618
- US6268343
Xultophy 100/3.6 was authorised for market use on 21 November, 2016.
Xultophy 100/3.6 is available in solution;subcutaneous dosage forms.
Drug patent challenges can be filed against Xultophy 100/3.6 from 26 September, 2019.
The generics of Xultophy 100/3.6 are possible to be released after 01 August, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-242) | Aug 08, 2022 |
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
XULTOPHY 100/3.6 family patents
